C
인벤테라
0007J0KOSDAQ40.5 / 100
Reference Date: 2026-10-23
Financial Score15.0 / 40
News Sentiment12.5 / 25
Momentum3.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 13.3% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Invenia is a biopharmaceutical company developing the 'Invinity™' polysaccharide-based nanotechnology platform to inhibit protein corona formation, enhance intrabody stability, and enable targeted drug delivery. The company focuses on addressing unmet medical needs through alternative MRI contrast agents and nano-medicines administered via oral or intra-articular injection methods.
Number of Employees
18people
Average Salary
78.2M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
4.98Industry Average 1.200.0Point
4.2x industry avg (risky)
ROE
-45.55Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
3.92Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 3.0 / 10 points
Revenue Growth Rate
1.5 / 3
Operating Profit Growth Rate
1.5 / 3
ROE Trend
0.0 / 4
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (9%, downtrend)
Current 9,030Won52-week high 35,25052-week low 6,220
1-month return1.0Point
1m -13.34% (falling)
Volume trend1.0Point
Volume dry-up
Detailed Disclosure
1 totalPositive 0Neutral 1Negative 0
- Neutral투자판단관련주요경영사항(임상시험계획승인신청등결정) (자기공명 췌담관조영술(MRCP) 특화 조영제 INV003액의 미국 FDA 제1상 임상시험계획(IND) 승인)2026-10-19